Slide 1: Cipla exchange filing letter: Investor Presentation
Cipla 25 January 2023 th (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Dalal Street Plot no. C/1, G Block, Mumbai 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIE
Slide 2: Investor Presentation Q3FY23
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q3FY23 25-1-2023
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Cipla Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including im
Slide 4: Q3FY23 Performance: Key Highlights
Q3FY23 Performance CLICK Continued TOtraction strong EDIT inMASTER One-IndiaTITLE and USSTYLE differentiated portfolio drive revenue and profitability Cipla KEY HIGHLIGHTS I I I Overall Revenue EBITDA Margin R&D Investment 1 11 - -- lil - •I -- Continued investment INR 5,810 Cr INR 1,408 Cr 24.2% I
Slide 5: Financial Performance – Q3FY23
Financial Performance – Q3FY23 CLICK TO EDIT MASTER TITLE STYLE Cipla Revenues INR 5,810 Cr EBITDA INR 1,408 Cr Revenue1 Break-up Q3 FY23 (Consolidated) Actuals API, 3% Others, 1% vs Q3 FY22 (INR Cr) International Total Revenue from Markets, 5,810 6% Operations 13% EBITDA 1,408 13% SAGA, EBITDA % of
Slide 6: Continued focus on building balance sheet strength
Continued focus on building balance sheet strength CLICK TO EDIT MASTER TITLE STYLE Cipla Total Debt1 Cash Balances2 Net Cash3 (INR Cr) (INR Cr) (INR Cr) 6,232 4,965 5,060 5,190 3,909 3,992 1,068 1,056 1,042 T Mar'22 Sept'22 Dec'22 Mar'22 Sept'22 Dec'22 Mar'22 Sept'22 Dec'22 1. Total debt includes l
Slide 7: One India: Strong execution across portfolio and distribution
One India (Rx + Gx+ CHL1): Strong execution across portfolio and CLICK TO distribution EDIT MASTER helping TITLE us drive STYLEacross the three businesses growth Cipla INR Cr INR Cr 7,644 7,609 2,518 2,563 Q3FY22 Q3FY23 YTD FY22 YTD FY23 ■ Prescription ■ Trade generics ■ Consumer health ■ Prescripti
Slide 8: Branded prescription business continues to deliver market beating growth
Our branded prescription business continues to deliver market CLICK beating TO EDIT growth MASTER driven by TITLE STYLE growing share of chronic therapies Cipla 7th consecutive quarter of market beating growth in core portfolio over previous year 17.9 42% 17.1 14.8 38% 12.8 29% 11.611.3 11.8 11.7 11
Slide 9: Global consumer wellness franchise improving health outcomes
Global consumer wellness franchise improving health outcomes CLICK TO EDIT MASTER TITLE STYLE Cipla One-India Flagship Brands 975+ • protyte· GMINIISlK ORS CIPCAL® INR Cr ↑ 28% ↑ 23% ↑ 5% ↑ 11% 9MFY23 revenue C/PLADINE tBlt41 CLOCIP 8.5% 0 ↑ 36% ↑ 24% ↑ 7% ↑ 30% Contribution of Global South Africa C
Slide 10: North America: Continued momentum on differentiated products
North America: Continued momentum on the back of expansion in CLICK share TO EDIT MASTER of differentiated TITLE STYLE products Cipla 10th consecutive quarter of growth in revenue over previous year 245 225 - North America Revenue ($m) YoY growth Lanreotide inj. launch Lenalidomide launch Leuprolide
Slide 11: North America: Continued momentum on differentiated products
North America: Continued momentum on the back of expansion in CLICK share TO EDIT MASTER of differentiated TITLE STYLE products Cipla North America @! I I Highest ever quarterly revenue driven by steady contribution from Lenalidomide, market share expansion in respiratory & peptide products, offsett
Slide 12: ANDA & NDA Portfolio & Pipeline
ANDA & NDA Portfolio & Pipeline (As on 31st December 2022) CLICK TO EDIT MASTER TITLE STYLE Cipla 14 59 9 4 19 2 8 78 1 43 8 8 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 1 ■ Cipla Ltd ■ PEFPAR ■ Invagen ■ Partnered ANDAs/NDAs 160 Approved + 19 Tentatively + 74 Under App
Slide 13: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access CLICK TO EDIT MASTER TITLE STYLE Cipla $ Mn Q3 Y-o-Y South Africa2 8 36 ❖ Supply challenges being addressed; evolving business mix between private and tender 23 16 12 ❖ In secondary terms, strong demand continues with overall South Afri
Slide 14: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE Cipla International Markets API Q3 Y-o-Y Q3 Y-o-Y INR Cr 738 762 INR Cr 150 147 $ Mn 98 93 $ Mn 20 18 Q3FY22 Q3FY23 Q3FY22 Q3FY23 Key Business Highlights Key Business Highlights ❖ $ revenue impacted by currency volatility; ❖ Continued gr
Slide 15: New Partnerships for Innovation
New Partnerships for Innovation Cipla CLICK TO EDIT MASTER TITLE STYLE Partnering in development of mRNA-based therapies ❑ Ethris GmbH is global leader in delivering mRNAs directly to the respiratory system including administration by inhalation Cipla ❑ Cipla signed definitive agreements for equity
Slide 16: ESG Update
ESG Update Cipla CLICK TO EDIT MASTER TITLE STYLE Continued Progress on ESG Goals • Healthy progress on renewable energy plan till date • Projects in water conservation • Captive Open Access Projects: initiated with multiple NGOs in 61 MWp completed field of Natural Resource Carbon • Onsite Roof-top
Slide 17: Continued progress on our strategic priorities
Continued progress on our strategic priorities Cipla CLICK TO EDIT MASTER TITLE STYLE Accelerate growth Building big prescription brands across Driving penetration and Consumer insighting driving portfolio ► .. in One-India chronic therapies, improved ~ • engine with sharp focus on; productivity and
Slide 18: Profit and Loss statement summary
Profit and Loss statement summary Cipla CLICK TO EDIT MASTER TITLE STYLE Q3 FY23 Q2 FY23 Q3 FY22 Particulars (INR Crores) (INR Crores) (INR Crores) Revenue from sale of products 5,730.1 5,759.3 5,442.9 Other operating income 80.0 69.3 36.0 Income from operations 5,810.1 5,828.5 5,478.9 Material cost
Slide 19: Balance sheet summary
Balance sheet summary Cipla CLICK TO EDIT MASTER TITLE STYLE Dec-22 Sep-22 Mar-22 Dec-22 Sep-22 Mar-22 Particulars Particulars (INR Crores) (INR Crores) (INR Crores) (INR Crores) (INR Crores) (INR Crores) Property, plant and equipment 5,077.6 5,080.0 5,164.4 Share capital 161.4 161.4 161.4 Capital w
Slide 20: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ankit Bhembre Investor.Relations@cipla.com For more information please visit www.cipla.com